Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

LAB WORKS, LLC

NPI: 1861900698 · HOMEWOOD, AL 35209 · Clinical Medical Laboratory · NPI assigned 01/15/2018

$41.64M
Total Medicaid Paid
912,295
Total Claims
823,149
Beneficiaries
128
Codes Billed
2019-03
First Month
2024-11
Last Month

Provider Details

Authorized OfficialEARL, ADAM (MANAGING PARTNER)
NPI Enumeration Date01/15/2018

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2019 550 $31K
2020 36,834 $2.23M
2021 172,792 $8.29M
2022 280,335 $12.27M
2023 246,560 $11.05M
2024 175,224 $7.77M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 65,032 55,002 $11.94M
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 61,132 51,780 $8.54M
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 84,982 78,801 $4.15M
87634 46,048 42,304 $1.89M
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 45,630 38,247 $1.78M
87581 54,313 44,679 $1.27M
87486 53,978 44,425 $1.27M
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 32,517 31,195 $1.26M
87541 41,793 39,336 $1.02M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 61,994 57,493 $993K
87496 33,289 31,559 $822K
87532 33,288 31,558 $822K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 46,185 43,859 $689K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 25,368 23,913 $622K
87481 10,700 8,170 $618K
87640 27,430 25,277 $520K
87653 21,707 19,934 $420K
87631 6,138 5,806 $363K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 2,867 2,638 $351K
87529 6,059 4,857 $243K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 2,021 1,947 $183K
87070 21,320 20,424 $169K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 7,146 6,725 $168K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 3,675 3,291 $151K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 8,413 6,603 $146K
84443 Thyroid stimulating hormone (TSH) 5,394 5,179 $106K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 4,316 4,177 $103K
87511 4,525 4,100 $103K
87507 518 510 $102K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 801 724 $73K
80053 Comprehensive metabolic panel 7,467 7,110 $73K
87641 3,730 3,435 $68K
80061 Lipid panel 5,166 4,976 $62K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 7,651 7,290 $59K
83036 Hemoglobin; glycosylated (A1C) 4,789 4,632 $49K
87086 Culture, bacterial; quantitative colony count, urine 4,704 4,496 $40K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 2,957 2,725 $32K
84439 3,808 3,656 $29K
82607 1,319 1,257 $18K
36415 Collection of venous blood by venipuncture 13,591 12,687 $18K
80055 396 370 $18K
82728 1,563 1,512 $17K
87500 833 766 $16K
87493 765 656 $15K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 201 190 $13K
83655 1,147 1,116 $13K
84480 813 788 $12K
87077 1,604 1,557 $12K
84481 866 822 $11K
86780 1,016 956 $11K
83540 1,800 1,736 $11K
83525 984 949 $10K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 2,057 1,914 $8K
84466 605 588 $8K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 404 381 $7K
86003 105 52 $7K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 379 356 $6K
86140 1,325 1,293 $6K
87088 609 589 $5K
83020 405 378 $4K
87498 239 217 $4K
83550 876 855 $4K
87184 684 660 $4K
88142 226 217 $4K
82105 269 252 $4K
86850 953 895 $4K
85027 771 752 $3K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 69 65 $3K
86665 81 80 $3K
87081 412 407 $3K
85652 1,092 1,057 $3K
82677 130 123 $3K
84702 266 245 $3K
86038 185 178 $2K
82746 258 234 $2K
84403 120 107 $2K
86703 170 161 $2K
87563 1,364 1,328 $2K
83735 410 376 $2K
87340 446 422 $2K
84681 147 147 $2K
86336 130 123 $2K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc 68 58 $2K
85045 420 413 $2K
83001 99 89 $1K
82947 488 445 $1K
86592 343 325 $1K
86664 76 75 $1K
86762 102 99 $1K
85007 290 285 $1K
86663 76 75 $1K
87503 6,412 5,811 $1K
86376 103 91 $922.37
82670 62 53 $846.35
86803 81 77 $846.00
85014 301 296 $797.45
87205 178 172 $767.19
81001 213 204 $585.96
84146 25 24 $552.00
82626 53 42 $550.02
84144 56 47 $505.18
82043 90 89 $440.86
80048 Basic metabolic panel (calcium, ionized) 68 63 $436.11
80076 54 54 $380.58
86900 411 389 $359.70
86901 411 389 $355.21
82533 51 43 $351.64
85046 78 78 $348.08
83003 49 42 $337.32
84432 48 41 $336.00
82570 48 48 $276.00
81511 29 29 $230.00
83002 12 12 $225.56
82785 31 27 $204.40
87186 21 21 $185.54
86141 16 15 $156.00
86431 32 31 $153.62
81003 67 63 $149.01
83021 14 14 $125.36
85018 26 26 $64.00
84550 13 12 $48.00
81005 21 21 $41.64
85004 60 59 $4.45
87501 53 51 $0.00
G0475 Hiv antigen/antibody, combination assay, screening 28 27 $0.00
85008 61 58 $0.00
85032 108 106 $0.00
86593 13 13 $0.00